Modeling software to create synthetic data based on real clinical datasets
Replica Analytics is developing modeling software to create synthetic data based on real clinical datasets. High quality synthetic data is increasingly sought after by researchers, the pharmaceutical industry, and other entrepreneurs who require the datasets to build new models and enable AI innovation in healthcare.
Algorithm to predict breast cancer patient response to neoadjuvant chemotherapy
Innovative technology consists of specialized hardware and algorithms for analyzing ultrasound RF-data. The algorithms quantitatively predict the responsiveness of breast tumours to standard chemotherapy by measuring tissue structural characteristics associated with tumour response prognosis.
Cellular Analytics
Cellular Analytics is founded upon a proprietary microfluidic platform that enables molecular characterization of cancer at the level of single circulating tumour cells. The technology quantitatively detects sensitivity to immune-oncology agents 'on-chip' at both significantly lower sample volumes and at a fraction of the cost.
Fusion Pharmaceuticals Inc.
A clinical stage company focused on developing novel radiotherapeutics for the treatment of cancer. Fusion is a spin-out from the Centre for Probe Development and Commercialization (CPDC) at McMaster University, Hamilton.
Turnstone Biologics Inc.
Novel bio-therapeutics for the treatment of cancer: Turnstone Biologics extends the boundaries of the emerging field of cancer immunotherapy. Turnstone’s Maraba virus technology is a first-in-class tumour targeted oncolytic vaccine. Building on the recent clinical validation of OVs, the Maraba virus technology combines potent tumour killing effects with the benefits of a cancer vaccine, increasing anti-tumour immunity.
A novel platform technology that simultaneously detects solid tumours using MRI and sensitizes cancer cells for maximized radiation therapy performance
Nanology Labs has developed a low toxicity MRI contrast agent which circumvents limitations of other agents currently available. The agent, Manganescan™, uses nanoparticles containing manganese to illuminate early stage tumors, including those in the brain.
A radially expandable access port to maximize the potential of laparoscopic surgical oncology
Recognizing a real unmet need, Xpan is developing expandable surgical access ports that aim to increase safety and efficiency of minimally invasive surgeries.
Development of WD40 Repeat Domain (WDR) Platform
OICR is developing a programme targeting multiple members of the WD40 repeat domain (WDR) family with small molecules. The large WDR family is involved in many multi-protein complexes functioning in epigenetics, transcription, DNA damage, protein degradation, metabolism and other growth regulating pathways.
Split Intein-Mediated Protein Ligation (SIMPL): a unique and disruptive system for detecting PPIs in real time
Development of a novel system to trap weak or transient protein-protein interactions (PPIs), unique for its tolerance for multiple experimental conditions and utility for drug discovery applications.
A radially expandable access port to maximize the potential of laparoscopic surgical oncology
Recognizing a real unmet need, Xpan is developing expandable surgical access ports that aim to increase safety and efficiency of minimally invasive surgeries.
A novel platform technology that simultaneously detects solid tumours using MRI and sensitizes cancer cells for maximized radiation therapy performance
Nanology Labs has developed a low toxicity MRI contrast agent which circumvents limitations of other agents currently available. The agent, Manganescan™, uses nanoparticles containing manganese to illuminate early stage tumors, including those in the brain.
Propellon Therapeutics Inc.
The development and commercialization of novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone modification. The overexpression of WDR5 and resulting deregulation of epigenetic mechanisms are implicated in various cancers and correlated with poor patient survival.
Novera Therapeutics Inc.
A biotherapeutics company focused on developing and commercializing therapies that improve patient outcomes in difficult-to-treat cancers. Their current focus is on the development of promising small molecule drug candidates for haematological cancers.
Fluorinov Pharma Inc. (acquired by Trillium Therapeutics)
This novel, best-in-class orally bioavailable proteosome inhibitor is being developed for the treatment of multiple myeloma and other cancers.
Hand-held device for detecting tumour margins during lumpectomies
Multi-Magnetics is developing a hand-held device that uses photoacoustic imaging to detect tumour margins and residual disease in the surgical cavity during breast-conserving (lumpectomy) surgery.
Small-molecule inhibitors that target cancer cell mitochondria
Development of novel small-molecule inhibitors that target cancer cell mitochondria, a fuel source that many cancer cells rely on during chemotherapy. The initial indication for this potential drug candidate is high-risk early breast cancer.
Scaling clinical expertise with AI to automate and improve the delivery of cancer care
Bridge7 uses AI to automate & improve the efficiency, consistency & quality of delivering cancer care. Bridge7 has commercialized the first automated treatment planning solution being used clinically.
Privacy Analytics Inc.
Privacy Analytics provides data anonymization services and software, empowering organizations to use sensitive data assets safely and responsibly for innovation that benefits everyone.
Triphase Accelerator Corporation
An Accelerator enterprise formed to expedite proof-of-concept (PoC) and development of pre-IND cancer therapies, advancing in-licensed, clinically enabled oncology assets with high-value potential in a shared risk model for the purpose of out-licensing or selling the technology to create value. Triphase has formed a strategic partnership with Celgene Corporation to enable the rapid development of PoC in important new cancer therapies of mutual interest.
DVS Sciences Inc. (acquired by Fluidigm Sciences)
A unique analytical instrument for high throughput and highly multiplexed analyses of biomarkers for research, clinical trials and personalized medicine.
2021: Air compression sleeve for treating breast cancer-related lymphedema
Air Microfluidic Systems Inc. is developing an air microfluidics-enabled active compression sleeve for treating breast cancer-related lymphedema.
PITCH PRESENTER: Run Ze Gao, Air Microfluidic Systems Inc.
2020: Scaling clinical expertise with AI to automate and improve the delivery of cancer care
Bridge7 uses AI to automate & improve the efficiency, consistency & quality of delivering cancer care. Bridge7 has commercialized the first automated treatment planning solution being used clinically.
PITCH PRESENTER: Meir Dick, Bridge7 Oncology
2019: A radially expandable access port to maximize the potential of laparoscopic surgical oncology
Recognizing a real unmet need, Xpan is developing expandable surgical access ports that aim to increase safety and efficiency of minimally invasive surgeries.
PITCH PRESENTER: Zaid Atto, Xpan Inc.
2018: ReFilx™ – A regenerative filler matrix for breast cancer patients
ReFilx™ is a novel polymeric soft tissue filler that provides breast cancer patients with a cosmetically superior, minimally-invasive and cost-effective solution for the permanent restoration of breast defects following lumpectomy.
PITCH PRESENTER: Soror Sharifpoor, Polumiros Inc.
2017: Development of a Multi-mechanistic Vaccinia Virus-based Platform for the Treatment of Pancreatic Cancer
The novel platform delivers sustained and amplified viral-mediated cell killing specific to pancreatic cancer (PCa) via the production of PCa cell-targeted amiR-containing exosomes.
PITCH PRESENTER: Brian Keller, Carolina Ilkow, The Ottawa Hospital Research Institute
Development of a Cloud Platform for Genomics Data Management, Analysis and Sharing
The platform intends to make it easier for stakeholders to form public and private data sharing networks, and systematize genotype-phenotype associations, patient matching, and recruitment through deterministic search and machine learning algorithms.
Inhibition of Kv1.3: Inducing Apoptosis and Impeding Cancer Cell Proliferation
Further development of promising potent compounds in triple-negative breast cancer models.
Universal CAR-T Therapy
Development of a universally compatible (allogeneic) source for the next generation of CAR-T therapies based on hematopoietic stem cells harvested from healthy donors.
ADC Linker Platform
Further development of novel cyclic and heterocyclic hydrazone-based linkers for antibody-drug-conjugates (ADC). These compounds allow “tuning” of the drug-release properties of the ADC to optimize various properties, such as plasma stability and lysosome drug release, according to the desired application(s).
Test to Predict Breast Cancer Patient Response to Anthracyclines
Further validation of novel diagnostic gene test to predict which patients benefit from anthracycline chemotherapy.
Automatic Analysis of Screening Mammograms for Breast Cancer
Clinical validation of a novel breast cancer screening algorithm that can identify select screening mammograms as ‘benign and requiring no further review’, thereby reducing the need for a radiologist consult.
DT1 Class of Agents for the Treatment of AML and Other Orphan Cancers
Development of DT-1 class of small molecules which possess selective cancer cell-killing activity and reduced toxicity due to a unique “cloaking” mechanism.
Development of a Cloud Platform for Genomics Data Management, Analysis and Sharing
The platform intends to make it easier for stakeholders to form public and private data sharing networks, and systematize genotype-phenotype associations, patient matching, and recruitment through deterministic search and machine learning algorithms.
Multi-Spectral X-ray Panel for Chest Imaging
Development of multi-spectral X-ray imagers that improve the quality and accuracy of chest X-rays, while helping to reduce the demand for CT cancer diagnostics.
Positron Emission Mammography (PEM) Imaging System to Detect Pre-Invasive Breast Cancers
Innovative solid-state PEM system that produces a higher resolution of the breast, while reducing radiotracer dose, compared to competitive PEM system.
Development of Heliotrope Bioinformatics Software Platform
Heliotrope is a bioinformatics software platform that enables informed and actionable clinical decision by facilitating the interpretation and translation of tumor genomic sequencing data using comprehensive databases.
Heliotrope Bioinformatics Software Platform
A bioinformatics software platform that enables informed and actionable clinical decision by facilitating the interpretation and translation of tumor genomic sequencing data using comprehensive databases.
2016: MY-osto-ME
An economical port, bag and belt system for urostomy patients that aims to reduce their rate of complications, facilitate application, and reduce social stigma; overall helping improve the quality of life of bladder cancer patients.
PITCH PRESENTER: Dr. Nicholas Power, London Health Sciences Centre
Cell Permeable Kv1.3 Antagonists: Novel Targeting of Apoptosis in Cancer Treatment
Evaluation of novel potassium channel antagonists, initially developed for neurodegenerative disorders, as cancer therapeutics.
Ganglioside-based Immonotherapy
Evaluation of survival benefit and preclinical proof of concept of a novel ganglioside-based cancer vaccine.
CYP26 Inhibitors for Treatment of Acute Myeloid Leukemia
Development of novel CYP26 inhibitors for the treatment of leukemia and myeloma with potential greater specificity and less toxicity than current inhibitors.
2015: ChemoTracker
A mobile health application that seeks to merge tracking of patients’ side effects and situations related to cancer treatments with patient-provider communication.
PITCH PRESENTER: Danielle Paes, FocusONCare
2014: Ultra-Low Dose Microbubbles for Cancer
A new manufacturing process that creates microbubbles that are only responsive to the ultrasound frequency used in cancer treatment, enabling significantly lower volumes and costs while potentially improving safety.
PITCH PRESENTER: Dr. Naomi Matsuura, Sunnybrook Research Institute
Ring Study to Evaluate the PRedicTive brEast Cancer Test (PRoTECT)
Evaluation of a Nanostring gene expression assay across three centres for its analytical reproducibility and accuracy in potentially guiding the selection of patient-specific therapies for early breast cancers.
External Clinical Validation Study of a Quantitative Ultrasound Spectral Analysis Platform
Use of clinical low frequency ultrasound for monitoring tumour response in women receiving neoadjuvant chemotherapy for locally advanced breast cancer.
A CEA Vaccine that Generates a Humoral Response to Break Tolerance
Evaluation of immune responses engendered in CEA transgenic mice by a vaccine formulation composed of a recombinant CEA N domain antigen and advanced adjuvant.
Cell-Mate Technology for Esophageal Cell Sampling
Support for the use of Cell-Mate Technology in a clinical trial for the Genome Canada project entitled "Early detection of patients at high risk of esophageal adenocarcinoma".
Cellax Nanoparticles for Enhanced Cancer Treatment
CellaxTM is a drug-polymer conjugate nanoparticle that when injected, selectively accumulates in tumours resulting in increased therapeutic benefits and reduced side effects.
Harmonic Medical Inc.
A system using ultrasound to both detect and treat tumours in bone and liver for the relief of pain without surgery and without expensive imaging equipment.
